Pfizer (NYSE:PFE) Stock Price Down 0.4% – What’s Next?

by · The Cerbat Gem

Pfizer Inc. (NYSE:PFE – Get Free Report)’s share price traded down 0.4% during mid-day trading on Tuesday . The stock traded as low as $26.13 and last traded at $26.14. 15,552,259 shares changed hands during trading, a decline of 59% from the average session volume of 37,534,734 shares. The stock had previously closed at $26.24.

Analyst Upgrades and Downgrades

PFE has been the topic of several recent analyst reports. Citigroup initiated coverage on shares of Pfizer in a research report on Friday, October 25th. They set a “neutral” rating and a $30.00 target price on the stock. StockNews.com raised shares of Pfizer from a “hold” rating to a “buy” rating in a report on Wednesday, October 9th. UBS Group lifted their target price on shares of Pfizer from $30.00 to $31.00 and gave the company a “neutral” rating in a research report on Wednesday, July 31st. Cantor Fitzgerald restated an “overweight” rating and issued a $45.00 target price on shares of Pfizer in a research report on Wednesday, October 23rd. Finally, Wells Fargo & Company lifted their price objective on Pfizer from $28.00 to $30.00 and gave the stock an “equal weight” rating in a report on Wednesday, July 31st. Eight analysts have rated the stock with a hold rating, six have issued a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $33.58.

Read Our Latest Stock Analysis on PFE

Pfizer Stock Down 0.2 %

The stock has a market capitalization of $148.36 billion, a PE ratio of 35.32, a P/E/G ratio of 0.85 and a beta of 0.67. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.60 and a current ratio of 1.00. The stock’s 50-day moving average price is $28.84 and its two-hundred day moving average price is $28.67.

Pfizer (NYSE:PFE – Get Free Report) last issued its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share for the quarter, beating the consensus estimate of $0.64 by $0.42. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. The firm had revenue of $17.70 billion during the quarter, compared to the consensus estimate of $14.92 billion. During the same period last year, the company earned ($0.17) earnings per share. The company’s revenue was up 31.2% on a year-over-year basis. As a group, analysts expect that Pfizer Inc. will post 2.96 EPS for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, December 2nd. Shareholders of record on Friday, November 8th will be given a $0.42 dividend. This represents a $1.68 dividend on an annualized basis and a yield of 6.42%. The ex-dividend date is Friday, November 8th. Pfizer’s dividend payout ratio (DPR) is 227.03%.

Insider Activity at Pfizer

In other Pfizer news, Director Scott Gottlieb purchased 1,000 shares of Pfizer stock in a transaction dated Wednesday, October 30th. The stock was purchased at an average price of $28.24 per share, with a total value of $28,240.00. Following the transaction, the director now directly owns 10,000 shares of the company’s stock, valued at $282,400. This trade represents a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 0.06% of the stock is owned by insiders.

Institutional Investors Weigh In On Pfizer

A number of institutional investors have recently bought and sold shares of the business. Olistico Wealth LLC bought a new position in Pfizer in the 2nd quarter worth approximately $25,000. MFA Wealth Advisors LLC bought a new position in shares of Pfizer during the second quarter worth $29,000. Gladius Capital Management LP grew its stake in Pfizer by 102.8% during the third quarter. Gladius Capital Management LP now owns 1,043 shares of the biopharmaceutical company’s stock valued at $30,000 after acquiring an additional 38,015 shares in the last quarter. Quarry LP bought a new stake in Pfizer in the 2nd quarter valued at $31,000. Finally, Financial Connections Group Inc. purchased a new stake in Pfizer in the 2nd quarter worth $34,000. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Company Profile

(Get Free Report)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

See Also